全文获取类型
| 收费全文 | 414篇 |
| 免费 | 31篇 |
| 国内免费 | 4篇 |
专业分类
| 儿科学 | 3篇 |
| 基础医学 | 41篇 |
| 临床医学 | 13篇 |
| 内科学 | 18篇 |
| 神经病学 | 3篇 |
| 特种医学 | 35篇 |
| 外科学 | 161篇 |
| 综合类 | 16篇 |
| 预防医学 | 3篇 |
| 药学 | 16篇 |
| 中国医学 | 1篇 |
| 肿瘤学 | 139篇 |
出版年
| 2024年 | 3篇 |
| 2023年 | 5篇 |
| 2022年 | 8篇 |
| 2021年 | 29篇 |
| 2020年 | 18篇 |
| 2019年 | 22篇 |
| 2018年 | 42篇 |
| 2017年 | 35篇 |
| 2016年 | 8篇 |
| 2015年 | 25篇 |
| 2014年 | 42篇 |
| 2013年 | 27篇 |
| 2012年 | 22篇 |
| 2011年 | 26篇 |
| 2010年 | 16篇 |
| 2009年 | 19篇 |
| 2008年 | 18篇 |
| 2007年 | 19篇 |
| 2006年 | 18篇 |
| 2005年 | 11篇 |
| 2004年 | 12篇 |
| 2003年 | 8篇 |
| 2002年 | 2篇 |
| 2001年 | 5篇 |
| 2000年 | 2篇 |
| 1999年 | 1篇 |
| 1997年 | 1篇 |
| 1996年 | 3篇 |
| 1995年 | 1篇 |
| 1991年 | 1篇 |
排序方式： 共有449条查询结果，搜索用时 15 毫秒
51.
Mustafa M. Haddad Grant D. Schmit A. Nicholas Kurup John J. Schmitz Stephen A. Boorjian Jennifer Geske R. Houston Thompson Matthew R. Callstrom Thomas D. Atwell 《Journal of vascular and interventional radiology : JVIR》2018,29(8):1122-1126
Purpose
To evaluate treatment outcomes with percutaneous cryoablation (PCA) based on renal cell carcinoma (RCC) histology.Methods and Materials
Patients treated with PCA for a solitary, sporadic stage T1a RCC from 2003 to 2016 were identified from a single institution’s renal ablation registry. Patients with multiple tumors, history of RCC, or genetic syndromes associated with RCC (n = 60); no specific RCC subtype determined from core biopsy (n = 66); RCC subtype other than clear-cell or papillary (n = 7); or less than 3 mo of follow-up imaging (n = 5) were excluded. In total, 173 patients met study inclusion criteria. Oncologic outcomes, clinical outcomes, and complications were evaluated based on tumor subtype.Results
Of the 173 patients who underwent PCA for a stage T1a RCC, 130 (75%) had clear-cell RCC (ccRCC) and 43 (25%) had papillary RCC (pRCC). Median tumor size was 2.9 cm (range, 1.3–4.0 cm). Technically successful cryoablation was achieved in all 173 patients. Local tumor recurrence developed in 6 patients with ccRCC (4.6%), new renal tumors developed in 1 patient (0.8%), and metastatic RCC developed in 1 patient (0.8%) who also had local tumor recurrence. No patients with pRCC showed local tumor recurrence, new renal tumors, or metastatic disease. The 5-year disease-free survival rate in patients with ccRCC was 88%, compared with 100% in patients with pRCC (P = .48). Nine patients (5.2%), all with ccRCC, experienced major complications (P = .11).Conclusions
Percutaneous ablation is a viable treatment option for patients with clinical stage T1a pRCC and ccRCC. Percutaneous ablation may be a very favorable treatment strategy particularly for pRCC. 相似文献52.
Osamu Ichiyanagi Sei Naito Hiromi Ito Takanobu Kabasawa Takafumi Narisawa Hidenori Kanno Yuta Kurota Masayuki Kurokawa Hiroki Fukuhara Toshihiko Sakurai Hayato Nishida Tomoyuki Kato Mitsunori Yamakawa Norihiko Tsuchiya 《Clinical genitourinary cancer》2018,16(5):e1029-e1058
Background
The objective was to explore the predictive markers of late recurrence (LR) > 5 years after curative nephrectomy for renal cell carcinoma (RCC).Patients and Methods
We retrospectively examined the data from 303 patients with localized clear cell RCC treated surgically at our institution from 1993 to 2011. Activation of the eukaryotic initiation factor (eIF)4E-binding protein 1 (4EBP1)/eIF4E axis at the mammalian target of rapamycin complex 1 (mTORC1) was evaluated in the tumor specimens. Weak, intermediate, and strong immunohistochemistry staining grades were defined for 4EBP1, phosphorylated 4EBP1, and eIF4E. The effects of clinicopathologic factors and activation level grades on tumor recurrence were analyzed using multivariate Cox regression models. To validate the present findings, we investigated clinical data from The Cancer Genome Atlas and protein/phosphoprotein data from corresponding patients from The Cancer Proteome Atlas.Results
Of the 303 patients, 31 and 16 patients developed early recurrence (ER, ≤ 5 years) and LR, respectively. The activation levels were comparable among the subcategories of pathologic TN stage, Fuhrman grade, and microvascular and capsular invasion. Pathologic stage ≥ T1b, Fuhrman grade 3/4, and an intermediate or strong activation level correlated significantly with overall recurrence and ER. Strong activation of the axis and pathologic stage ≥ T1b were identified as independent predictors of LR. Only 2 patients with weak activation experienced recurrence (1 each with ER and LR). Similar results were confirmed by the analyses of The Cancer Genome Atlas and The Cancer Proteome Atlas data.Conclusion
The activation level of the axis in RCC tissues could independently predict for recurrence and differentially affect the timing of recurrence. 相似文献53.
Lubomir Bodnar Rafał Stec Szczepan Cierniak Agnieszka Synowiec Gabriel Wcisło Marzena Jesiotr Robert Koktysz Paweł Chrom Cezary Szczylik 《Clinical genitourinary cancer》2018,16(4):257-265
Background
The aim of the present study was to search for predictive and prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus among the components of the WNT/β-catenin pathway.Patients and Methods
In a prospective, single-arm, phase II study, patients with mRCC received everolimus (10 mg/d) in a 30-day cycle. We performed a prospectively planned evaluation of the potential biomarkers of the WNT/β-catenin pathway.Results
The serum level of soluble E-cadherin (sE-cadherin) in patients with RCC was significantly greater than that in the controls (71.62 ± 22.28 pg/mL vs. 54.26 ± 10.317 pg/mL; P = .0069). After 2 cycles of everolimus therapy, we observed a significance increase in sE-cadherin (from 71.81 ± 21.18 pg/mL to 77.50 ± 28.212 pg/mL; P = .0151). The Dickkopf-1 protein levels in the study and control groups were not significantly different (P = .2135). The favorable independent predictors for everolimus therapy were normal lactate dehydrogenase level before treatment (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.28-0.98; P = .0443) and low sE-cadherin level (HR, 0.54; 95% CI, 0.29-0.98; P = .0422). On multivariate analysis, we observed that worse overall survival was seen in patients with a lower regression coefficient of sE-cadherin after 2 cycles of treatment (HR, 2.60; 95% CI, 1.23-5.52; P = .0128), an increased corrected calcium level (HR, 3.09; 95% CI, 1.21-7.88; P = .0180), and an increased lactate dehydrogenase level before treatment (HR, 1.98; 95% CI, 1.02-3.83; P = .0426).Conclusion
WNT/β-catenin component expression in patients with mRCC had no effect on progression-free survival or overall survival. However, we found that the sE-cadherin level might interact with response to everolimus therapy, although confirmation in future studies is needed. 相似文献54.
François-Xavier Nouhaud France Blanchard Richard Sesboue Jean-Michel Flaman Jean-Christophe Sabourin Christian Pfister Frédéric Di Fiore 《Clinical genitourinary cancer》2018,16(4):e795-e805
Background
Gene copy number variations (CNVs) have been reported to be frequent in renal cell carcinoma (RCC), with potential prognostic value for some. However, their clinical utility, especially to guide treatment of metastatic disease remains to be established. Our objectives were to assess CNVs on a panel of selected genes and determine their clinical relevance in patients who underwent treatment of metastatic RCC.Patients and Methods
The genetic assessment was performed on frozen tissue samples of clear cell metastatic RCC using quantitative multiplex polymerase chain reaction of short fluorescent fragment method to detect CNVs on a panel of 14 genes of interest. The comparison of the electropherogram obtained from both tumor and normal renal adjacent tissue allowed for CNV identification. The clinical, biologic, and survival characteristics were assessed for their associations with the most frequent CNVs.Results
Fifty patients with clear cell metastatic RCC were included. The CNV rate was 21.4%. The loss of CDKN2A and PLG was associated with a higher tumor stage (P < .05). The loss of PLG and ALDOB was associated with a higher Fuhrman grade (P < .05). The loss of ALDOB was also associated with a worse Heng prognostic score (95% vs. 66%; P = .029) and lower 24-month survival rate (18% vs. 58%; P = .012). The loss of both ALDOB and PLG was frequent (32%) and was associated with a higher tumor stage and grade (P < .05).Conclusion
As expected, we showed that several CNVs were associated with clinical relevance, especially those located on CDKN2A, PLG, and ALDOB, in a homogeneous cohort of patients with clear cell metastatic RCC. 相似文献55.
56.
Alcohol consumption,variability in alcohol dehydrogenase genes and risk of renal cell carcinoma 
下载免费PDF全文
下载免费PDF全文 Samuel O. Antwi Jeanette E. Eckel‐Passow Nancy D. Diehl Daniel J. Serie Kaitlynn M. Custer Kevin J. Wu John C. Cheville David D Thiel Bradley C. Leibovich Alexander S. Parker 《International journal of cancer. Journal international du cancer》2018,142(4):747-756
Alcohol consumption has been associated inversely with renal cell carcinoma (RCC) risk; however, no study has examined effect modification by germline variation in alcohol‐metabolizing genes. We investigated whether the association between alcohol intake and RCC risk is modulated by germline variants in alcohol dehydrogenase genes in a large case–control study. Data from 652 RCC cases and 1,366 non‐cancer controls were analyzed. Alcohol intake was assessed using a standardized risk factor questionnaire. Three previously genotyped polymorphisms in ADH6 and ADH7 with the TaqMan assay were examined. Odds ratios (ORs) and 95% confidence interval (CI) were calculated using logistic regression, adjusting for covariates. Compared to non‐drinkers, ever consumption of alcohol was associated with lower RCC risk (OR = 0.52, 95% CI = 0.42–0.65). Analysis with cubic spline regression curve showed a “J‐shaped” relationship between alcohol drinks/day and RCC risk, such that there was no added benefit against RCC for consumption of more than two drinks/day. We observed effect modification by variation in rs1154454 (ADH7) (pinteraction = 0.007); a per unit increase in alcohol drink/day was associated with 35% lower RCC risk among non‐minor allele carriers, a 27% lower risk among those who carry one copy of the minor allele, but no association was observed among those with two copies of the minor allele. These findings indicate that alcohol consumption is associated with lower RCC risk. Consuming more than two drinks a day does not confer additional protection against RCC. The association between alcohol intake and RCC risk appears to be modulated by inter‐individual germline variation in alcohol‐metabolizing genes. 相似文献
57.
Exome sequencing and case–control analyses identify RCC1 as a candidate breast cancer susceptibility gene 下载免费PDF全文
下载免费PDF全文 Aouatef Riahi Hoda Radmanesh Peter Schürmann Natalia Bogdanova Robert Geffers Rym Meddeb Maher Kharrat Thilo Dörk 《International journal of cancer. Journal international du cancer》2018,142(12):2512-2517
Breast cancer is a genetic disease but the known genes explain a minority of cases. To elucidate the molecular basis of breast cancer in the Tunisian population, we performed exome sequencing on six BRCA1/BRCA2 mutation‐negative patients with familial breast cancer and identified a novel frameshift mutation in RCC1, encoding the Regulator of Chromosome Condensation 1. Subsequent genotyping detected the 19‐bp deletion in additional 5 out of 153 (3%) breast cancer patients but in none of 400 female controls (p = 0.0015). The deletion was enriched in patients with a positive family history (5%, p = 0.0009) and co‐segregated with breast cancer in the initial pedigree. The mutant allele was lost in 4/6 breast tumors from mutation carriers which may be consistent with the hypothesis that RCC1 dysfunction provides a selective disadvantage at the stage of tumor progression. In summary, we propose RCC1 as a likely breast cancer susceptibility gene in the Tunisian population. 相似文献
58.
Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK) 下载免费PDF全文
下载免费PDF全文 Shankar Siva MD PhD MBBS FRANZCR Alexander V. Louie MD MSc PhD FRCPC Andrew Warner MSc Alexander Muacevic MD Senthilkumar Gandhidasan MD FRANZCR Lee Ponsky MD Rodney Ellis MD Irving Kaplan MD Anand Mahadevan MD William Chu MD MSc FRCPC Anand Swaminath MD FRCPC Hiroshi Onishi MD Bin Teh MD Rohann J. Correa MD PhD Simon S. Lo MD FACR Michael Staehler MD 《Cancer》2018,124(5):934-942
59.
Hakmin Lee Jong Jin Oh Seok Soo Byun Chang Wook Jeong Cheol Kwak Byong Chang Jeong Seong Soo Jeon Hyun Moo Lee Han-Yong Choi Seong Il Seo 《Urologic oncology》2017,35(6):379-385
Objective
Although partial nephrectomy (PN) is the standard treatment for localized clinical T1a renal cell carcinoma (RCC), treatment of larger renal tumors is controversial. We evaluated the oncological outcomes and perioperative complications after radical and PN for RCC ≥4 cm.Patients and methods
We retrospectively analyzed the data of 2,373 patients surgically treated for nonmetastatic RCC with clinical T1b or T2 (≥4 cm). The propensity scores for surgery type were calculated, and the partial group was matched to the radical group in a 1:3 ratio. The oncological outcomes were compared using Kaplan-Meier analysis and multivariate Cox regression models were used to identify the independent predictors of progression-free, cancer-specific, and overall survival.Results
All differences in preoperative clinical characteristics disappeared after matching. There were no significant differences in progression-free, cancer-specific, or overall survival between the partial and radical groups in the matched cohort. The patients’ age, tumor size, cellular grade, and pathologic stage were independent predictors for all 3 survival outcomes. However, early complications (<30 d postoperative) were significantly more common in the partial group (P<0.001). In a subgroup analysis of the patients with clinical T2 stage, there were no significant differences in all 3 survival outcomes.Conclusions
The partial and radical nephrectomy groups had equivalent oncological outcomes. Although the early complication rate was significantly higher after PN, it should be considered as a valuable treatment option even in patients with clinical T1b or higher RCC. 相似文献60.